TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.